Coherus Biosciences | CHRS - L'Utile Ante Imposte





L'Utile Ante Imposte Cambiamento Data
AbbVie USD 5.57B 2.9B 2026-03
Acadia Pharmaceuticals USD 3.98M 22.34M 2026-03
Akebia Therapeutics USD -11.24M 12.39M 2025-12
ALKERMES USD -61.93M 122.3M 2026-03
Alnylam Pharmaceuticals USD 221.65M 60.52M 2026-03
Amarin USD -852K 7.26M 2025-12
Amgen USD 1.51B 2.41B 2025-12
Baxter International USD -756M 877M 2025-12
Biogen USD 377.7M 433.7M 2026-03
BioMarin Pharmaceutical USD 141.2M 168.36M 2026-03
Bristol-Myers Squibb USD 1.47B 1.64B 2025-12
Coherus Biosciences USD -46.35M 90.86M 2025-12
Eli Lilly USD 8.27B 1.03B 2025-12
Fujifilm JPY 104.44B 4.16B 2026-03
Gilead Sciences USD 2.08B 1.56B 2025-12
Ironwood Pharmaceuticals USD 68.02M 30.2M 2025-09
Merck USD 3.42B 3.32B 2025-12
Myriad Genetics USD 4.6M 3.4M 2025-12
Pacira USD 571K 8.95M 2025-12
Perrigo USD -1.33B 1.35B 2025-12
Pfizer USD 5.18B 6.82B 2026-03
PTC Therapeutics USD -2.46M 136.62M 2026-03
Regeneron Pharmaceuticals USD 1.04B 719.6M 2025-12
Sarepta Therapeutics USD 343.17M 750.85M 2026-03
Teva Pharmaceutical Industries USD 753M 662M 2026-03
Vertex Pharmaceuticals USD 1.25B 78.1M 2026-03
Xencor USD -128.64M 124.37M 2026-03
Zoetis USD 761M 126M 2025-12